Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Appointed director
|
Semler Scientific, Inc. (SMLR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
05/10/2023 |
8-K
| Quarterly results |
03/21/2023 |
8-K
| Quarterly results
Docs:
|
"CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 37,323 22,079 CASH AND CASH EQUIVALENTS, END OF PERIOD $ 23,014 $ 37,323 Supplemental Disclosure of Cash Flow Information: Cash paid for taxes $ 2,400 $ 2,647 Exercised put option of 211,928 common stock in SYNAPS Dx for 40,922 $ — $ 2,230 common stock of the company Page 7 of 9 About Semler Scientific, Inc.:" |
|
05/02/2022 |
8-K
| Quarterly results |
02/28/2022 |
8-K
| Quarterly results |
11/01/2021 |
8-K
| Quarterly results |
05/03/2021 |
8-K
| Quarterly results |
03/01/2021 |
8-K
| Quarterly results |
11/05/2020 |
8-K
| Quarterly results |
05/04/2020 |
8-K
| Quarterly results |
03/03/2020 |
8-K
| Quarterly results |
10/30/2019 |
8-K
| Quarterly results |
04/29/2019 |
8-K
| Quarterly results |
02/27/2019 |
8-K
| Quarterly results |
10/26/2018 |
8-K
| Quarterly results |
07/31/2018 |
8-K
| Quarterly results |
05/01/2018 |
8-K
| Quarterly results |
02/28/2018 |
8-K
| Quarterly results |
10/31/2017 |
8-K
| Quarterly results |
08/02/2017 |
8-K
| Quarterly results |
05/09/2017 |
8-K
| Form 8-K - Current report |
03/10/2017 |
8-K
| Form 8-K - Current report |
10/28/2016 |
8-K
| Quarterly results |
07/29/2016 |
8-K
| Form 8-K - Current report |
04/29/2016 |
8-K
| Form 8-K - Current report |
02/19/2016 |
8-K
| Quarterly results |
10/30/2015 |
8-K
| Quarterly results |
07/31/2015 |
8-K
| Quarterly results |
05/01/2015 |
8-K
| Quarterly results |
02/06/2015 |
8-K
| Quarterly results |
11/03/2014 |
8-K
| Quarterly results
Docs:
|
"Semler Reports Third Quarter 2014 Financial Results PORTLAND, Ore. – October 31, 2014 – Semler Scientific, Inc. , an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today reported financial results for the third quarter and nine months ended September 30, 2014. “In the third quarter of 2014, Semler’ s performance accelerated,” said Doug Murphy-Chutorian, M.D., chief executive officer of Semler. “We moved forward on executing our business model by initiating more relationships with insurance plans, moving pilot trials to completed orders, and expanding installations with established clients.” FINANCIAL RESULTS" |
|
07/25/2014 |
8-K
| Quarterly results
Docs:
|
"Semler Reports Second Quarter 2014 Financial Results PORTLAND, Ore. – July 25, 2014 – Semler Scientific, Inc. , an emerging medical risk assessment company that develops patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today reported financial results for the second quarter and six months ended June 30, 2014. “The second quarter of 2014 continued to be productive for Semler,” said Doug Murphy-Chutorian, M.D., chief executive officer of Semler. “We attracted seasoned talent to our team, grew revenue, built relationships with insurance plans and progressed in product development.” FINANCIAL RESULTS" |
|
04/22/2014 |
8-K
| Quarterly results |
|
|